Medicis invests in Revance; gets option to RT001; terminated
- Specialty Pharmaceuticals
- Topical Delivery
- Includes Equity
- Product Purchase
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.